Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer
Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer.
The data from the Phase 2 trial shows that the treatment is meeting “outcome measures for safety and demonstrating encouraging clinical activity.” It was tested on two groups comprising 45 patients.
58% of patients experienced a treatment-related adverse event of grade 3 or higher. The companies said that “these rates were similar to those observed with Padcev monotherapy.” Six patients discontinued treatment due to treatment related adverse events, most commonly peripheral sensory neuropathy.
The confirmed Objective Response Rate (ORR) of 73% included 15.6% patients who achieved complete responses and 57.8% who had partial responses after a median follow up of 11.5 months.
Roger Dansey, Chief Medical Officer at Seattle Genetics, commented on the results and said: “These updated data are encouraging and provide support for the recently initiated Phase III EV-302 trial that includes an arm evaluating Padcev in this platinum-free combination in the first-line settings.”
Additional tests will evaluate Padcev as a monotherapy or together with Keytruda and chemotherapy in first-line metastatic disease. The study will also assess Padcev in combination with Keytruda in muscle-invasive diseases, as well as with Keytruda in the second-line setting.
Padcev was approved by the FDA back in December for adults with locally advanced or metastatic urothelial cancer.
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
Merck (known as MSD outside of the US and Canada) has announced the approval of …